Provectus Biopharmaceuticals Will Hold Its 2016 First Quarter Business Update Conference Call on
Tuesday, May 10, 2016, at 4 pm Eastern Daylight Time
Call to Be Webcast, Available for Digital Replay
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or the
"Company”), announced today that it will host its 2016 first quarter business update conference call on Tuesday, May 10, 2016 at 4
pm Eastern Daylight Time.
Management will provide a business update on PV-10 and PH-10 to the investment community and answer questions from
investors.
Those who wish to participate in the conference call may telephone 877-407-4019 from the U.S. International callers may
telephone 201-689-8337 approximately fifteen minutes before the call. A webcast will also be available at www.provectusbio.com.
A digital replay will be available by telephone approximately two hours after the completion of the call until August 31, 2016
and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, and using the Conference ID #
13636789.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel
investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing
potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has
received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical
investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed
Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and
psoriasis. Information about these and the Company’s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit
the Company’s website at www.provectusbio.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws.
These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's
current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate,"
"believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms.
Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking
statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A
of our Annual Report on Form 10-K for the year ended December 31, 2015) and the following:
- our determination, based on guidance from the FDA, whether to proceed with or without a partner with
the fully enrolled phase 3 trial of PV-10 to treat locally advanced cutaneous melanoma and the costs associated with such a trial
if it is necessary to complete (versus interim data alone);
- our determination whether to license PV-10, our investigational drug product for melanoma and other
solid tumors such as cancers of the liver, if such licensure is appropriate considering the timing and structure of such a
license, or to commercialize PV-10 on our own to treat melanoma and other solid tumors such as cancers of the liver;
- our ability to license PH-10, our investigational drug product for dermatology, on the basis of our
phase 2 atopic dermatitis and psoriasis results, which are in the process of being further developed in conjunction with
mechanism of action studies; and
- our ability to raise additional capital if we determine to commercialize PV-10 and/or PH-10 on our
own, although our expectation is to be acquired by a prospective pharmaceutical or biotech concern prior to
commercialization.
Provectus Biopharmaceuticals, Inc.
Peter R. Culpepper, 866-594-5999 #30
Interim CEO, COO
or
Porter, LeVay & Rose, Inc.
Marlon Nurse, DM, SVP, 212-564-4700
Investor Relations
or
Allison + Partners
Todd Aydelotte, 646-428-0644
Managing Director - Media Relations
View source version on businesswire.com: http://www.businesswire.com/news/home/20160504005209/en/